NYSE:RCUSBiotechs
Does Arcus Biosciences’ (RCUS) AVEO Tie-Up Hint At A New Combo-First RCC Strategy?
Arcus Biosciences recently announced a clinical supply agreement with AVEO Oncology to test its investigational HIF-2α inhibitor casdatifan in combination with AVEO’s tivozanib in a new ARC-20 study cohort for patients with advanced clear cell renal cell carcinoma who previously received HIF-2α inhibitor therapy.
An interesting aspect of this collaboration is that both companies retain development and commercial rights to their respective drugs, potentially influencing how future combination...